Explore facts and recommendations for pharmacological treatments for rare renal disorders.
We didn't find any resources that match your selection.
Please adjust your filter(s) and try again.
PHYOX Clinical Development Program
An overview of the PHYOX clinical development program evaluating nedosiran for the treatment of primary hyperoxaluria.
PHYOX2 infographic
This infographic provides an overview of PHYOX2, the pivotal randomized study of nedosiran in PH1 or PH2
Continuing Education
Find accredited opportunities in rare renal disorders education.
Rare Renal Disorders
Rare Renal Disorders
Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.